Drug Database
Back to search

Finland· FI-REL-REL10368

Ixel

A milnacipran product containing milnacipran hydrochloride, registered in Finland by Pierre Fabre Pharma Norden AB. The same ATC class is registered in 6 of our 19 countries.

ATC N06AX17

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedIxelATCN06AX17REGISTER NO.FI-REL-REL10368PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about milnacipran hydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Milnacipran is registered in 6 of 19 countries.

Countries holding a registration under ATC N06AX17 (milnacipran), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 3 of them publish a price we can compare per daily dose
Search milnacipran products by name

Milnacipran · ATC N06AX17

6 / 19 countries

  • Finlandprice
  • Franceprice
  • Germany
  • Japan
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of milnacipran costs, country by country.

Normalised to the WHO defined daily dose (0.1 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Milnacipran · price per daily dose (0.1 g)

USD · FX 28 Sept 2026

  • US United States$24.47 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Milnacipran hydrochloride
Manufacturer
Pierre Fabre Pharma Norden AB
Country
Finland (FI)
ATC code
N06AX17
ATC class
Milnacipran
Defined daily dose
0.1 g, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

194 interactions on record for milnacipran.

Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check milnacipran against other medicinesHow interaction checks work

Milnacipran · interactions on record

194 records

  • 27 severe
  • 167 moderate

Most severe, free to view

  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • DolasetronA04AA04severe
  • PalonosetronA04AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Milnacipran in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All milnacipran products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Austria · Milnacipran Glenmark, Milnacipran Rivopharm
  • Germany · Milnacipran Glenmark, Milnacipran Holsten
  • France · Milnacipran Arrow, Milnacipran Eg
  • Luxembourg · Milnacipran Micro Labs

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f844e275-ab95-4f85-9b08-9d7c565c0d5e
GET /v1/drugs/f844e275-ab95-4f85-9b08-9d7c565c0d5e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.1",
  "form": "kapseli, kova",
  "route": null,
  "ddd_unit": "g",
  "strength": "50 mg",
  "atc_label": "milnasipraani",
  "ma_number": "13572",
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": null,
  "fimea_rel_id": "REL10368",
  "authorised_at": "1998-09-21"
}
API referenceMCP serverPlans

See everything about milnacipran.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console